NEW YORK (GenomeWeb) – Deutsche Bank has initiated coverage on the life sciences and diagnostics sector, saying it is "generally positive" on the outlook for its fundamentals, even though company valuations are near historical highs, and assigned a Neutral outlook for the group of eight stocks.

Analyst Shawn Bevec assigned Buy ratings to shares of Fluidigm, Myriad Genetics, and Thermo Fisher Scientific, and Hold ratings to shares of Agilent Technologies, Bruker, Illumina, PerkinElmer, and Waters. He also listed Myriad and Thermo Fisher as "top" picks.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.